Evidence map›Paper›PMID 38766239›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Diversity and selection analyses identify transmission-blocking antigens as the optimal vaccine candidates in

Ilinca I Ciubotariu, Bradley K Broyles, Shaojun Xie, Jyothi Thimmapuram, Mulenga C Mwenda, Brenda Mambwe, Conceptor Mulube, Japhet Matoba, Jessica L Schue, William J Moss and 3 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ilinca I CiubotariuDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.ORCID 0000-0002-6549-0771
Bradley K BroylesDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.
Shaojun XieBioinformatics Core, Purdue University, West Lafayette, Indiana, USA.
Jyothi ThimmapuramBioinformatics Core, Purdue University, West Lafayette, Indiana, USA.
Mulenga C MwendaPATH-Malaria Control and Elimination Partnership in Africa (MACEPA), National Malaria Elimination Centre, Lusaka, Zambia.
Brenda MambwePATH-Malaria Control and Elimination Partnership in Africa (MACEPA), National Malaria Elimination Centre, Lusaka, Zambia.
Conceptor MulubePATH-Malaria Control and Elimination Partnership in Africa (MACEPA), National Malaria Elimination Centre, Lusaka, Zambia.
Japhet MatobaMacha Research Trust, Choma, Zambia.
Jessica L SchueDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
William J MossThe W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0001-6579-3513
Daniel J BridgesPATH, Lusaka, Zambia.
Qixin HeDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.ORCID 0000-0003-1696-8203
Giovanna CarpiDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.ORCID 0000-0001-8137-6285

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A highly effective vaccine for malaria remains an elusive target, at least in part due to the under-appreciated natural parasite variation. This study aimed to investigate genetic and structural variation, and immune selection of leading malaria vaccine candidates across the Methods: We analyzed 325 Findings: Among the ten antigens analyzed, only three in the transmission-blocking vaccine category display Interpretations: These findings offer valuable insights into the selection of optimal vaccine candidates against Funding: Purdue Department of Biological Sciences; Puskas Memorial Fellowship; National Institute of Allergy and Infectious Diseases (U19AI089680).

Identifiers

PMID38766239
PMCPMC11100930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.